Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Pharmaceutical Contract Sales Outsourcing (CSO) Market 

5.1. COVID-19 Landscape: Pharmaceutical Contract Sales Outsourcing (CSO) Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, By Service

8.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Service, 2023-2032

8.1.1. Personal Promotion

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Non-personal Promotion

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, By Therapeutic Area

9.1. Pharmaceutical Contract Sales Outsourcing (CSO) Market, by Therapeutic Area, 2023-2032

9.1.1. Cardiovascular Disorders

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Oncology

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Metabolic Disorders

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Neurology

9.1.4.1. Market Revenue and Forecast (2020-2032)

9.1.5. Orthopedic Diseases

9.1.5.1. Market Revenue and Forecast (2020-2032)

9.1.6. Infectious Diseases

9.1.6.1. Market Revenue and Forecast (2020-2032)

9.1.7. Others

9.1.7.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Pharmaceutical Contract Sales Outsourcing (CSO) Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Service (2020-2032)

10.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Service (2020-2032)

10.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2020-2032)

Chapter 11. Company Profiles

11.1. IQVIA Inc.

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Syneos Health Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Parexel International Corporation

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Pharmaceutical Product Development (PPD) LLC

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. inVentiv Health Inc. (part of Syneos Health)

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. ICON plc

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Publicis Touchpoint Solutions, Inc.

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. PRA Health Sciences, Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. The Medical Affairs Company (TMAC)

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Ashfield Healthcare Communications Group (part of UDG Healthcare plc)

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms